ARS Pharmaceuticals (SPRY) Other financing activities (2024 - 2026)

ARS Pharmaceuticals has disclosed Other financing activities across 3 years of filings, most recently posting $62000.0 for Q1 2026.

• Other financing activities for Q1 2026 came in at $62000.0, down 91.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $823000.0 (down 62.73% YoY), and the FY2020 annual result was $2.6 million, changed N/A from the prior year.
• Other financing activities came in at $62000.0 for Q1 2026 at ARS Pharmaceuticals, up from -$2.7 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $2.7 million in Q2 2025 to a low of -$2.7 million in Q3 2025.
• The 3-year median for Other financing activities is $545000.0 (2024), against an average of $329428.6.
• Peak annual rise in Other financing activities reached 394.86% in 2025, while the deepest fall reached 491.32% in 2025.
• ARS Pharmaceuticals' Other financing activities stood at $680000.0 in 2024, then tumbled by 491.32% to -$2.7 million in 2025, then jumped by 102.33% to $62000.0 in 2026.
• The last three Other financing activities figures came in at $62000.0 (Q1 2026), -$2.7 million (Q3 2025), and $2.7 million (Q2 2025), per Business Quant data.